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Recurrent cytogenetic abnormalities in chronic lymphocytic leukemia (CLL), namely deletions 
of chromosomes 11q, 13q, 17p and trisomy 12 (+12), define subgroups of patients with 
different clinical behavior and response to treatment
1
. We and others previously reported a 
minor fraction of CLL cases with co-existing trisomies of chromosomes 12 and 19 who share 
specific clinicobiological characteristics
2-4
. However, the cohort was small, thus precluding 
definitive conclusions. Here, taking advantage of a large, multi-institutional series, we 
confirm and significantly extend previous observations through the identification of 
subgroups of +12 CLL cases harboring particular concurrent trisomies demonstrating 
distinctive clinicobiological profiles.  
In an unselected cohort of 4486 CLL patients with available classic cytogenetic (n=4285) or 
high-density 250K single nucleotide polymorphism (SNP)-array data (n=201) we identified 
712 cases (16% of the cohort) carrying +12
5
. The median time from diagnosis to 
cytogenetic/SNP analysis was 1.5 months (range, 0-194); the majority of cases included in 
survival analysis were untreated prior to testing (94%). The study was approved by the local 
Ethics Review Committees. Details about the study cohort and the methodologies utilized 
are provided in the Supplementary Material. 
Of the 712 +12 CLL cases, 86 (12% or 2% of the entire cohort) harbored multiple trisomies; 
68/86 cases (78% or 1.5% of the entire cohort) had co-existing +19 (+12+19 CLL), while the 
remaining 18/86 cases (22% or 0.5% of the entire cohort) were negative for +19 and instead 
carried other co-existing extra chromosome(s) (+12,+other-non19 CLL) (Supplemental Table 
1, Supplemental Figure 1).  
Amongst +12+19 cases, 49/68 (72%) harbored additional numerical and/or structural 
aberrations. Trisomy 18 was the predominant co-existing abnormality and was detected in 
42/68 cases (62%) (Figure 1A). Comparison of +12+19 cases with/without +18 revealed no 
significant differences (regarding age and stage at diagnosis, gender, IGHV mutational status, 
CD38 expression and clinical outcome, data not shown), suggesting that +18 might represent 
a secondary event, probably related to clonal evolution. This claim is also supported by our 
unpublished FISH data using chromosome 12 and 18 centromeric probes in cases with 
+12+18+19, revealing cells with +12 alone, cells with +12+18 but not cells with +18 alone. 
Additional structural abnormalities, primarily concerning chromosome 13q, were observed 
in 12/63 (18%) cases, of whom 10  also carried +18. Only 1/23 (4%) and 3/59 (5%) cases with 
available data carried mutations in the NOTCH1 and TP53 genes, respectively
6, 7
; none of 
these cases carried +18.   
The +12+19 CLL subgroup concerned relatively young patients (median age at diagnosis: 59 
years). In keeping with our previous report, all +12+19 CLL cases with available data (n=23) 
expressed surface IgG. Considering the low frequency of CLL cases with switched 
immunoglobulin (IG) in their B-cell receptors (BcR), this finding is highly suggestive of a 
particular immunopathogenetic process in this patient subgroup
8
. This claim was further 
supported by the remarkable bias to lambda light chain expression in this particular 
cytogenetic subgroup [22/32 cases (69%) with available data], raising the intriguing 




All but one +12+19 CLL case with available information (47/48, 98%) carried immunoglobulin 
heavy variable (IGHV) genes impacted to some degree by somatic hypermutation (SHM), 
leading to IGHV genes with <100% germline identity. Following the 98% germline identity 
cut-off value, only 2/48 (4%) cases were classified as IG-unmutated CLL (U-CLL), whereas the 
remaining 46 carried numerous SHMs and were classified as IG-mutated CLL (M-CLL). 
Despite this, in keeping with our previous study, the majority of +12+19 cases (41/60, 68%) 
expressed CD38
2
. Unexpectedly, 23/37 (62%) +12+19 cases were found to express 
monoclonal paraprotein detectable by immunofixation electrophoresis with identical heavy 
(gamma) and light chain to that present on the surface of the circulating CLL cells. This is 
significantly higher compared to generic CLL cohorts and merits further investigation
11
, 
especially since paraproteinemia in CLL has not thus far been associated with a particular 
cytogenetic aberration. Of note, amongst +12+19 cases, no differences were identified 
regarding other clinicobiological features, including CD38 positivity, between cases 
with/without paraproteinemia.  
Turning to the +12+other-non+19 CLL subgroup, the co-existing cytogenetic aberrations 
were exclusively numerical: trisomy 3 predominated (7/18 cases, 39%), followed by 
trisomies 18 and 22 in 6 (33%) and 4 (22%) cases, respectively (Figure 1B). Similar to what 
was reported above, most cases (7/9, 78%) belonged to the M-CLL category and expressed 
CD38 (11/17 cases, 65%). Recurrent gene mutations were very rare, indeed only 1/13 (8%) 
patients carried a TP53 mutation, whereas no NOTCH1 mutations were identified
6
.  
Perhaps the most notable features of the +12+other-non+19 subgroup concerned the high 
incidence of clinical/laboratory autoimmune manifestations
12
 (4/9 cases with available 
information, 45%) and other malignancies
13
 (5/10 cases with additional information, 50%). 
Regarding the former, these included: autoimmune hemolytic anemia (n=2) as well as a 
positive direct antiglobulin (n=1) and rheumatoid factor test (n=1); 3/5 of these cases never 
required treatment for their CLL. Other co-existing malignancies concerned: prostate cancer 
(n=2), bladder cancer (n=1), adenocarcinoma of the uterus (n=1) and basal cell carcinoma of 
the skin (n=1); one of these 5 cases never received any treatment for CLL, while among the 
remaining 4, three were diagnosed with the other malignancy prior to receiving any CLL-
specific treatment. Altogether, the link with malignancy identified in our study is intriguing, 
however it requires further investigation in larger patient cohorts. 
Comparative assessment of the two subgroups reported above, namely +12+19 CLL and 
+12+other-non+19 CLL, revealed significant differences regarding heavy IgG-isotype 
expression (p<0.0001) as well as the incidence of del(13q) (p=0.001), autoimmune 
manifestations (p=0.013) and second malignancies (p=0.018) (Table 1). Comparisons were 
also made to 65 cases of the present series carrying isolated +12 as detected by classic 
cytogenetic analysis, illustrating that the two subgroups reported here display distinct 
subgroup-biased profiles (Table 1). In particular, both subgroups were enriched for M-CLL 
compared to isolated +12 CLL (p<0.001 and p=0.032 for +12+19 and +12+other-non+19, 
respectively). The +12+19 CLL subgroup also differed significantly from isolated +12 cases 
regarding age at diagnosis (younger amongst the former), higher incidence of IgG-switched 
heavy and lambda light chains, CD38 positivity as well as higher incidence of co-existing 
del(13q) (p=0.001). Moving on to the +12+other-non+19 CLL subgroup, comparison to 
isolated +12 cases disclosed a significantly higher incidence of autoimmune manifestations 
and other malignancies. Finally, both subgroups experienced a more indolent clinical course 
compared to cases with isolated +12, reflected in a significantly longer overall survival (OS). 
In fact, whereas a median OS of 7.9 years was observed for cases with isolated +12, the 
median OS for +12+other-non+19 subgroup was 16 years while that of the +12+19 subgroup 
had not yet been reached (p=0.033 and p=0.013, respectively). These findings corroborate 
previous reports that cytogenetic complexity defined by solely numerical aberrations within 
CLL should not be axiomatically considered as an unfavorable prognostic marker. That said, it 
should be acknowledged that the favorable clinical outcome within +12,+19 and +12,+other-
non19 subgroups might be attributed to their enrichment for M-CLL (Supplemental Figure 2). 
Amongst various host- and tumor-related parameters assessed for their 
prognostic/predictive relevance, cytogenetic aberrations and recurrent gene mutations have 
attracted the greatest interest
7, 14, 15
. Trisomy 12 is the second most frequent recurrent 
chromosomal aberration in CLL and is associated with clinical and biological heterogeneity, 
potentially linked to the presence of additional genomic aberrations. This concept is 
reinforced by our present findings regarding the biological background and clinical 
presentation/outcome of subgroups of +12 CLL patients defined by the presence of extra 
trisomies. These subgroups seem to differ from patients with isolated +12 while also 
exhibiting a constellation of biological and clinical features whose co-occurrence is rather 
unlikely to be fortuitous. This conclusion is also supported by our query for CLL cases with 
trisomy 19 in the Mitelman Database of Chromosome Aberrations and Gene Fusions in 
Cancer (http://cgap.nci.nih.gov/Chromosomes/Mitelman) which retrieved 66 cases of which 
56 (85%) displayed a co-existing +12. Taking all the above into consideration, +19 in CLL 
appears to be heavily biased to patients carrying +12, alluding to a unique pathway of clonal 
evolution. As for the +12+other-non+19 subgroup, although caution is warranted due to the 
low number of cases, the lack of any structural chromosomal aberration and paucity of 
recurrent gene mutations is noteworthy.  
In conclusion, we report the existence of subgroups within +12 CLL defined by the presence 
of extra trisomies, associated with subgroup-biased profiles of potential clinical relevance. 
The biological mechanisms underlying both the acquisition of additional chromosomes and, 
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 Table 1. Comparison of +12+19 versus +12+other-non+19 versus isolated +12 cases. Due to 
multiple testing, the Bonferroni correction is applied per line and each individual hypothesis 





B: +12+ other-non+19 
n=18 
C: isolated +12 
n=65 
p-value 
A vs B 
p-value 
A vs C 
p-value 
B vs C 
Male gender 52/68 (76%) 12/18 (67%) 43/65 (66%) 0.382 0.249 1.000 
Median age at 
diagnosis (years) 
59 67 67 0.007 0.0001 0.76 
<55 years 24/65 (37%) 0/14 (0%) 2/57 (4%) 0.031 <0.0001 0.509 
Binet A 50/61 (82%) 14/17(82%) 47/57 (82%) 1.000 1.000 1.000 
Binet B 5/61 (8%) 2/17 (12%) 8/57 (14%) 0.642 0.384 1.000 
Binet C 6/61 (10%) 1/17 (6%) 2/57 (4%) 1.000 0.274 0.586 
M-CLL
1
 46/48 (96%) 7/9 (78%) 23/61 (38%) 0.113 <0.0001 0.032 
IgG isotype 23/23 (100%) 1/8 (12%) 8/45 (18%) <0.0001 <0.0001 1.000 
Lambda light 
chain expression 
22/32 (69%) 2/8 (25%) 14/46 (30%) 0.042 0.001 1.000 
CD38 expression
2
 41/60 (67%) 11/17 (65%) 25/56
3
 (45%) 0.776 0.014 0.814 
del(13q) 27/51 (53%) 0/11 (0%) 13/48
4
 (27%) 0.001 0.014 0.100 
del(11q) 0/53 (0%) 0/10 (0%) 1/47 (2%) 1.000 0.47 1.000 
TP53abn
5
 3/59 (5%) 1/13 (8%) 4/56 (7%) 0.557 0.712 1.000 
NOTCH1 1/23 (4%) 0/7 (0%) 4/37
6
 (11%) 1.000 0.640 1.000 
IG spike 23/37 (62%) 2/8 (25%) No data 0.113 - - 
Autoimmunity 2/33 (6%) 4/9 (50%) 0/22 (0%) 0.013 0.511 0.004 
Other 
malignancy 
4/48 (8%) 5/10 (55%) 4/43 (9%) 0.018 1.000 0.042 
1: CLL with mutated IGHV genes; 2: cut-off for positivity: 30%; 3: amongst +12/M-CLL, CD38 high expression: 
3/17 (19%); 4: amongst +12/M-CLL, del(13q): 8/16 (50%); 5: TP53abn: deletion of chromosome 17p and/or 





Figure 1. Genomic profile of: (A) +12,+19 and (B) +12,+other-non+19 CLL. The rows 
correspond to the specific lesion indicated while the columns represent individual patients. 
Colored: positive (black), negative (dark grey), no data (light grey). del(13q): deletion of 
chromosome 13q detected by FISH, del(11q): deletion of chromosome 11q detected by FISH; 
TP53 abnormality: deletion of chromosome 17p and/or TP53 mutation.  
Figure 2. Kaplan-Meier curves for overall survival (OS). The +12,+19  and +12+other-non19 
CLL cases demonstrated significantly prolonged OS compared to CLL cases with isolated +12 
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Supplementary material  
Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 
12: the accompanying chromosome makes a difference 
 
The Supplementary material contains information regarding the patient series and the 
methodologies utilized.  
 
Classic Cytogenetic and FISH analysis 
For metaphase induction, 106 per mL peripheral blood mononuclear cells were cultured 
using two different protocols. More specifically, until 2008, cells were cultured for 72 and 96 
hours in RPMI 1640 medium with 20% fetal calf serum and phorbol-12-myristate-13-acetate 
(TPA) at 50ng/mL; colcemid (0.01 μg/ml) was added 45 min before harvest. Since 2008, 
metaphases were obtained after culturing in RPMI 1640 medium with 20% fetal calf serum 
in the presence of the immunostimulatory CpG-oligonucleotide DSP30 and interleukin 2 (IL-
2) (200 U/mL); after 48 hours, colcemid (0.015 μg/ml), was added for an additional 24 hours 
prior to the preparation of chromosomes. Hypotonic treatment was performed using 0.075 
M KCl, and fixation of the chromosomes was accomplished using a methanol:glacial acetic 
acid (3:1) fixative solution. Chromosome preparation and staining was performed according 
to standard protocols. A minimum of 15 mitotic cells were examined and karyotypes were 
classified according to the International System for Human Cytogenetic Nomenclature (ISCN) 
2009. Karyotypes obtained before 2009, were re-classified following the ISCN from 2013. 
Interphase fluorescence in situ hybridization (FISH) analysis was conducted using probes to 
detect the recurrent genomic aberrations in CLL. More specifically probes were used to 
detect (del)11q23 (LSI ATM and CEP11), del(13q14) (D13S319 and LSI13q34) for del(17p13) 
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Microarray single nucleotide polymorphism analysis (250K Affymetrix arrays) 
SNP-array experiments were performed according to the standard protocols for Affymetrix 
GeneChip® Mapping NspI-250K arrays and as previously described1. 
 
Analysis of gene mutations 
Mutational screening was performed for the following genes: NOTCH1: entire exon 34 or 
targeted analysis for del7544-45/p.P2514Rfs*4; TP53: exons 4-8 as previously described2.  
 
CD38 expression 
CD38 expression was assessed with flow-cytometry (threshold for positivity: 30%). 
 
PCR amplification and sequence analysis of IGHV-IGHD-IGHJ rearrangements 
PCR amplification and sequence analysis of IGHV-IGHD-IGHJ rearrangements were 
performed on either genomic DNA (gDNA) or complementary DNA (cDNA), as previously 
described or following the BIOMED-2 protocol3. PCR amplicons were subjected to direct 
sequencing on both strands. Sequence data were analyzed using the IMGT® databases and 
the IMGT/V-QUEST tool (http://www.imgt.org). Only productive rearrangements were 
evaluated. Output data from IMGT/V-QUEST for all productive IGHV-IGHD-IGHJ 
rearrangements were parsed, reorganized, and exported to a spreadsheet through the use 
of computer programming. Information was extracted regarding IG gene repertoires, VH 
CDR3 length and amino acid sequence and the % germline identity. 
 
Statistical analysis 
Descriptive analysis included frequency distributions for all the categorical variables. 
Associations regarding categorical variables were assessed using the Chi-square or Fisher's 
exact test for independence, in case the evaluated group included less than 20 cases. Overall 
survival (OS) was calculated using the date of diagnosis and the date of death or last follow-
up. Kaplan Meier survival analysis and the log-rank test were used to assess differences in OS 
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between patient subgroups for different variables. All tests were two sided and significance 
was defined as a p value less than 0.05. Statistical analysis was performed using the Statistica 
Software 10·0 (StatSoftInc, Tulsa,OK) and R-3.2.1 programming language. 
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Supplemental Table 1. +12 CLL carrying additional trisomies. 



































































































*1: according to high-density 250K single nucleotide polymorphism analysis 
*2: verified by FISH analysis 
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Supplemental Figure 1. Left: proportion of +12 CLL within the whole CLL cohort. Right: 
Proportion of +12,+19 and +12,+othet-non19 CLL within +12 CLL. 
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Supplemental Figure 2. Kaplan-Meier curves for overall survival (OS) within cases carrying 
mutated IGHV genes (M-CLL). No significant difference between cases with +12,+19 and 
those with  isolated +12 is observed, however this could be due to low numbers. 
 















 +12,+19, M-CLL, n=35
 isolated +12, M-CLL, n=18
p=0.18
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